Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed trials have results

Key Signals

5 recruiting1 with results

Enrollment Performance

Analytics

Phase 1
5(71.4%)
Phase 2
2(28.6%)
7Total
Phase 1(5)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials
NCT05024175Recruiting

Long-term Follow-up of Subjects Treated With CAR T Cells

Role: lead

NCT06026319Phase 1Recruiting

CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma

Role: lead

NCT05020444Phase 1Recruiting

TriPRIL CAR T Cells in Multiple Myeloma

Role: lead

NCT07388277Phase 1Not Yet Recruiting

CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis

Role: lead

NCT05660369Phase 1Recruiting

CARv3-TEAM-E T Cells in Glioblastoma

Role: lead

NCT04150913Phase 2Completed

A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity

Role: lead

NCT06550141Phase 2Recruiting

Emapalumab Prevention of CAR-T Cell Associated Toxicities

Role: lead

NCT04136275Phase 1Completed

CAR-37 T Cells in Hematologic Malignancies

Role: lead

All 8 trials loaded